Dr Luke on the Background of the KEYNOTE-716 Trial in High-Risk Melanoma
August 18th 2023Jason Luke, MD, FACP, discusses the background of the phase 3 KEYNOTE-716 trial of pembrolizumab vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma, highlighting previous data from the trial that led to the 36-month follow-up report.
Read More
CSCC: Translating Cemiplimab Data Into Practice
April 19th 2023Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.
Read More
Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates
April 12th 2023A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.
Read More
Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials
April 12th 2023Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.
Read More